Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year The Motley Fool 14:28 Thu, 18 Jun
CRISPR Therapeutics (CRSP) Stock Valuation Check After Recent Pullback And Conflicting DCF And P/B Signals Simply Wall St 10:20 Sat, 13 Jun
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know Zacks 00:03 Thu, 11 Jun
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? The Motley Fool 18:28 Mon, 08 Jun
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential The Motley Fool 17:51 Wed, 03 Jun
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out The Motley Fool 08:21 Wed, 03 Jun
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking The Motley Fool 17:41 Mon, 01 Jun
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? The Motley Fool 17:45 Sun, 31 May
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? The Motley Fool 01:46 Tue, 26 May
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know Zacks 15:10 Tue, 19 May
